

#8235 Store at -20°C

Annexin A2 (D11G2) Rabbit mAb


Cell Signaling
TECHNOLOGY®

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
WB, W-S, IHC-P, IF-IC, FC-FP	H M R Mk B Pg	Endogenous	38	Rabbit IgG	#P07355	302

Product Usage Information

Application

Western Blotting
Simple Western™
Immunohistochemistry (Paraffin)
Immunofluorescence (Immunocytochemistry)
Flow Cytometry (Fixed/Permeabilized)

Dilution

1:1000
1:50 - 1:250
1:200 - 1:800
1:100 - 1:200
1:50 - 1:200

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody.

Specificity / Sensitivity

Annexin A2 (D11G2) Rabbit mAb recognizes endogenous levels of total annexin A2 protein. This antibody is not known or predicted to cross-react with other annexin family members.

Species predicted to react based on 100% sequence homology:

Dog, Horse

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Phe307 of human annexin A2 protein.

Background

Annexin A2 (ANXA2), also known as lipocortin II or calpactin-1 heavy chain, is a 36 kDa member of the annexin superfamily that binds phospholipids and other proteins in a calcium-dependent manner via annexin repeats (1). Annexin A2 contains four such repeats through which it mediates protein-protein and protein-lipid interactions (1-4). It forms a constitutive heterotetramer with S100A10, acting as a bridge between the actin cytoskeleton, plasma membrane, and endocytotic vesicle machinery (5-7). Originally identified as a protein inhibitor of phospholipase A2, annexin A2 has subsequently been shown to interact with an array of protein and non-protein partners, including F-actin, spectrin, SNARE complexes, RNA, and virus particles (4,6,8,9). Annexin A2 has also been shown to have receptor-like activity and is detected on the surface of macrophages and vascular endothelial cells where it mediates macrophage activation and Factor Xa signaling, respectively (10-13). Upregulation of annexin A2 at the cell surface is thought to be modulated by phosphorylation at Tyr23 by Src (14-18). Interestingly, phosphorylation at Tyr23 has recently been shown to be required for cell surface expression of annexin A2 where it mediates motility, invasiveness, and overall metastatic potential of certain pancreatic cancer cells (19,20). Annexin A2 has also been shown to be heavily phosphorylated on serine residues in response to PKC activation via a pleiotropic mechanism (21-23). For a complete list of curated phosphorylation sites on annexin A2, please see PhosphoSitePlus® at www.phosphosite.org.

Background References

1. Barton, G.J. et al. (1991) *Eur J Biochem* 198, 749-60.
2. Gerke, V. and Weber, K. (1985) *EMBO J* 4, 2917-20.
3. Glenney, J.R. and Tack, B.F. (1985) *Proc Natl Acad Sci USA* 82, 7884-8.
4. Gerke, V. and Weber, K. (1984) *EMBO J* 3, 227-33.
5. Illien, F. et al. (2010) *Biochim Biophys Acta* 1798, 1790-6.
6. Umbrecht-Jenck, E. et al. (2010) *Traffic* 11, 958-71.
7. Jung, M.J. et al. (2010) *Exp Cell Res* 316, 1234-40.
8. Filipenko, N.R. et al. (2004) *J Biol Chem* 279, 8723-31.
9. Wright, J.F. et al. (1994) *Biochem Biophys Res Commun* 198, 983-9.
10. Bhattacharjee, G. et al. (2008) *Circ Res* 102, 457-64.
11. Pizzo, S.V. (2008) *Circ Res* 102, 389-91.
12. Swisher, J.F. et al. (2007) *J Leukoc Biol* 82, 1174-84.

13. Deora, A.B. et al. (2004) *J Biol Chem* 279, 43411-8.
14. Huang, K.S. et al. (1986) *Cell* 46, 191-9.
15. Erikson, E. et al. (1984) *Mol Cell Biol* 4, 77-85.
16. Glenney, J.R. (1985) *FEBS Lett* 192, 79-82.
17. Morel, E. and Gruenberg, J. (2009) *J Biol Chem* 284, 1604-11.
18. de Graauw, M. et al. (2008) *Mol Cell Biol* 28, 1029-40.
19. Nedjadi, T. et al. (2009) *Br J Cancer* 101, 1145-54.
20. Zheng, L. et al. (2011) *PLoS One* 6, e19390.
21. Gould, K.L. et al. (1986) *Mol Cell Biol* 6, 2738-44.
22. Luo, W. et al. (2008) *Mol Carcinog* 47, 934-46.
23. He, K.L. et al. (2011) *J Biol Chem* 286, 15428-39.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

WB: Western Blotting **W-S:** Simple Western™ **IHC-P:** Immunohistochemistry (Paraffin)
IF-IC: Immunofluorescence (Immunocytochemistry) **FC-FP:** Flow Cytometry (Fixed/Permeabilized)

Cross-Reactivity Key

H: human **M:** mouse **R:** rat **Hm:** hamster **Mk:** monkey **Vir:** virus **Mi:** mink **C:** chicken **Dm:** D. melanogaster
X: Xenopus **Z:** zebrafish **B:** bovine **Dg:** dog **Pg:** pig **Sc:** S. cerevisiae **Ce:** C. elegans **Hr:** horse
GP: Guinea Pig **Rab:** rabbit **All:** all species expected

Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
 The Annexin V-FITC conjugate is a product manufactured for Cell Signaling Technology, Inc. by TAU Technologies BV.
 All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.